文献速递心脑血管急症重症综合管理与镇静镇痛

秋水仙碱对接受大型胸科非心脏手术患者围术期心房颤动及心肌损伤的影响(COP-AF):一项国际随机试验

Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial.
PubMed 文献 · Lancet · 2023-08-25
一句话结论大型非心脏胸科手术患者围术期口服秋水仙碱0.5 mg每日两次未显著降低临床重要围术期房颤或MINS,但增加非感染性腹泻风险。

COP-AF是一项在11个国家45个中心开展的随机试验,纳入3209例55岁及以上接受大型非心脏胸科手术的患者,1:1随机接受口服秋水仙碱0.5 mg每日两次或安慰剂,术前4小时内启动并持续10天。主要终点为14天随访期内临床重要围术期房颤和MINS:房颤发生率为秋水仙碱组6.4% vs 安慰剂组7.5%(HR 0.85,95%CI 0.65-1.10;ARR 1.1%,95%CI -0.7至2.8;p=0.22),MINS为18.3% vs 20.3%(HR 0.89,95%CI 0.76-1.05;ARR 2.0%,95%CI -0.8至4.7;p=0.16),均未达统计学显著。脓毒症或感染复合终点秋水仙碱组6.4% vs 安慰剂组5.2%(HR 1.24,95%CI 0.93-1.66),非感染性腹泻秋水仙碱组8.3% vs 安慰剂组2.4%(HR 3.64,95%CI 2.54-5.22)。

要点

  • 大型非心脏胸科手术患者围术期口服秋水仙碱0.5 mg每日两次(术前4小时内启动,持续10天)未显著降低14天内临床重要围术期房颤(6.4% vs 7.5%,HR 0.85,95%CI 0.65-1.10;p=0.22)。
  • 秋水仙碱未显著降低MINS发生率(18.3% vs 20.3%,HR 0.89,95%CI 0.76-1.05;ARR 2.0%,95%CI -0.8至4.7;p=0.16)。
  • 非感染性腹泻在秋水仙碱组明显更常见(8.3% vs 2.4%,HR 3.64,95%CI 2.54-5.22)。
  • 脓毒症或感染复合终点秋水仙碱组6.4% vs 安慰剂组5.2%(HR 1.24,95%CI 0.93-1.66),未达统计学显著。

适用人群与场景

  • 年龄55岁及以上、接受大型非心脏胸科手术的患者(COP-AF纳入标准)。
  • 研究在11个国家45个中心开展,随机分组后随访14天。

处置流程与药物剂量

  • 秋水仙碱组:口服秋水仙碱0.5 mg每日两次,术前4小时内开始,持续10天;安慰剂组给予匹配安慰剂。

研究设计与关键结果

  • 研究类型:国际随机对照试验(COP-AF),45个中心,11个国家,纳入3209例患者(平均年龄68岁[SD 7],男性1656例[51.6%]),1:1随机分配至秋水仙碱组(1608例)或安慰剂组(1601例)。
  • 主要终点之一临床重要围术期房颤:秋水仙碱组103例(6.4%)vs 安慰剂组120例(7.5%),HR 0.85(95%CI 0.65-1.10),ARR 1.1%(95%CI -0.7至2.8),p=0.22。
  • 主要终点之一MINS:秋水仙碱组295例(18.3%)vs 安慰剂组325例(20.3%),HR 0.89(95%CI 0.76-1.05),ARR 2.0%(95%CI -0.8至4.7),p=0.16。
  • 安全性终点脓毒症或感染复合终点:秋水仙碱组103例(6.4%)vs 安慰剂组83例(5.2%),HR 1.24(95%CI 0.93-1.66)。
  • 安全性终点非感染性腹泻:秋水仙碱组134例(8.3%)vs 安慰剂组38例(2.4%),HR 3.64(95%CI 2.54-5.22)。

证据类型、等级与局限

  • 证据类型:国际多中心随机对照试验(RCT),采用计算机化网络系统随机分组、按中心分层,对医护人员、患者、数据收集者和裁定者设盲,意向性分析。
  • 试验注册号:ClinicalTrials.gov NCT03310125。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于55岁及以上接受大型非心脏胸科手术的患者,围术期口服秋水仙碱0.5 mg每日两次(术前4小时内启动,持续10天)未能显著降低14天内临床重要围术期房颤或MINS的发生率。
  • 该方案增加非感染性腹泻风险(8.3% vs 2.4%,HR 3.64,95%CI 2.54-5.22),原文描述为多为良性。
  • 脓毒症或感染复合终点在秋水仙碱组数值上更高(6.4% vs 5.2%,HR 1.24,95%CI 0.93-1.66),未达统计学显著。
  • 原文结论:秋水仙碱未显著减少临床重要房颤或MINS,但增加了多为良性的非感染性腹泻风险。

指南或共识出处

  • COP-AF试验,发表于Lancet,注册号NCT03310125。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Higher levels of inflammatory biomarkers are associated with an increased risk of perioperative atrial fibrillation and myocardial injury after non-cardiac surgery (MINS). Colchicine is an anti-inflammatory drug that might reduce the incidence of these complications.

METHODS: COP-AF was a randomised trial conducted at 45 sites in 11 countries. Patients aged 55 years or older and undergoing major non-cardiac thoracic surgery were randomly assigned (1:1) to receive oral colchicine 0·5 mg twice daily or matching placebo, starting within 4 h before surgery and continuing for 10 days. Randomisation was done with use of a computerised, web-based system, and was stratified by centre. Health-care providers, patients, data collectors, and adjudicators were masked to treatment assignment. The coprimary outcomes were clinically important perioperative atrial fibrillation and MINS during 14 days of follow-up. The main safety outcomes were a composite of sepsis or infection, and non-infectious diarrhoea. The intention-to-treat principle was used for all analyses. This trial is registered with ClinicalTrials.gov, NCT03310125.

FINDINGS: Between Feb 14, 2018, and June 27, 2023, we enrolled 3209 patients (mean age 68 years [SD 7], 1656 [51·6%] male). Clinically important atrial fibrillation occurred in 103 (6·4%) of 1608 patients assigned to colchicine, and 120 (7·5%) of 1601 patients assigned to placebo (hazard ratio [HR] 0·85, 95% CI 0·65 to 1·10; absolute risk reduction [ARR] 1·1%, 95% CI -0·7 to 2·8; p=0·22). MINS occurred in 295 (18·3%) patients assigned to colchicine and 325 (20·3%) patients assigned to placebo (HR 0·89, 0·76 to 1·05; ARR 2·0%, -0·8 to 4·7; p=0·16). The composite outcome of sepsis or infection occurred in 103 (6·4%) patients in the colchicine group and 83 (5·2%) patients in the placebo group (HR 1·24, 0·93-1·66). Non-infectious diarrhoea was more common in the colchicine group (134 [8·3%] events) than the placebo group (38 [2·4%]; HR 3·64, 2·54-5·22).

INTERPRETATION: In patients undergoing major non-cardiac thoracic surgery, administration of colchicine did not significantly reduce the incidence of clinically important atrial fibrillation or MINS but increased the risk of mostly benign non-infectious diarrhoea.

FUNDING: Canadian Institutes of Health Research, Accelerating Clinical Trials Consortium, Innovation Fund of the Alternative Funding Plan for the Academic Health Sciences Centres of Ontario, Population Health Research Institute, Hamilton Health Sciences, Division of Cardiology at McMaster University, Canada; Hanela Foundation, Switzerland; and General Research Fund, Research Grants Council, Hong Kong.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Conen D, Ke Wang M, Popova E, et al. Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial. Lancet. 2023. PMID: 37640035. doi:10.1016/S0140-6736(23)01689-6

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。